



E.I.D. - Parry (India) Limited

Regd.Office : Dare House, 234,N.S.C. Bose Road, Parrys Corner, Chennai 600 001, India.

Tel: 91.44.25306789 Fax : 91.44.25341609 / 25340858

CIN : L24211TN1975PLC006989

Website : www.eidparry.com

December 22, 2017

BSE Limited
1st Floor, New Trading Ring, Rotunda
Building, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra Kurla Complex Bandra (E),
Mumbai - 400 051

Dear Sir/Madam,

Ref: E.I.D.- Parry (India) Limited Scrip Code (500125/ EIDPARRY)

Sub: Intimation on the outcome of the Board Meeting held on December 22, 2017 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Sale of the Company's Bio Pesticides Business and Divestment of entire shareholding in Parry America Inc, a wholly owned subsidiary.

We wish to inform you that the Board of Directors of the Company at their meeting held today approved the following:

- (a) Sale of the Company's Bio Pesticides Business as a going concern by way of a slump sale to Coromandel International Limited, a subsidiary of the Company.
- (b) Divestment of entire shareholding of the Company in Parry America, Inc., a wholly owned subsidiary to Coromandel International Limited, a subsidiary of the Company.

The Bio-Pesticides business is engaged in the manufacture and marketing of Neem based Azadirachtin Technical and Formulations, Plant extract based Bio-stimulants, Micronutrients Microbial biopesticides, etc and their Azadirachtin brands are established globally. The business has a manufacturing facility in Tamilnadu and manufactures Azadirachtin using technology sourced from M/s Trifolio, Germany which it has improved over time. The business has an R&D unit which has carried out extensive study on Microbial & household pesticide segment and progressed to an advanced stage to initiate registration for approval and access market.

Parry America, Inc, a 100% subsidiary of E.I.D.-Parry (India) Limited headquartered in US sources Azadirachtin technical from Bio-Pesticides business in India, manufactures formulations and markets the products in North and South America, Australia and Japan.

The above will be subject to the required approvals being obtained including that of the shareholders of the Company under Section 188 of Companies Act, 2013.

The details that are required to be disclosed under aforesaid Regulation 30 are enclosed as "Annexure A" as per Annexure I of SEBI circular dated September 9, 2015.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For E.I.D. - PARRY (INDIA) LIMITED

G.JALAJA
Company Secretary

Encl.: a/a





E.I.D. - Parry (India) Limited

Regd. Office : Dare House, 234, N.S.C. Bose Road, Parrys Corner, Chennai 600 001, India.

Tel: 91.44.25306789 Fax : 91.44.25341609 / 25340858

CIN : L24211TN1975PLC006989

Website : www.eidparry.com

Annexure A

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Annexure I (A) (1) of SEBI circular dated September 9, 2015.

S. No	Particulars	Sale of the Company's Bio Pesticides Business	Divestment of entire shareholding in Parry America Inc, a wholly owned subsidiary
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;	Details relating to the Bio-Pesticides business for the financial year 2016-17: Turnover: Rs. 121.74 Crs (4.92%) Net worth: Rs 82.76 Crs (5.60%)	Details relating to Parry America Inc for the financial year 2016-17: Turnover: Rs 55.31 Crs (USD 8.525 mn) Net worth: Rs 15.46 Crs (USD 2.383 mn)
2.	Date on which the agreement for sale has been entered into;	Term Sheet has been signed on December 22, 2017. Definitive agreements would be executed in due course.	
3.	The expected date of completion of sale/disposal;	April 1, 2018	
4.	Consideration received from such sale/disposal;	The consideration for the sale is Rs 302.61 crore and the Consideration would be appropriately adjusted for the difference, if any, between the Working Capital reckoned for the valuation and the actual working capital as at the Closing Date. The consideration will be settled in cash.	The consideration for the sale is Rs 35.40 crore
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Coromandel International Limited, India's second largest Phosphatic fertiliser player, is in the business of Fertilisers, Specialty Nutrients, Crop Protection and Rural Retail. The Company manufactures a wide range of fertilizers, making it a leader in its addressable markets. Coromandel International Ltd is a subsidiary Company of E.I.D.- Parry (India) Limited and EID Parry holds 60.62% in the Equity of Coromandel.	
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Transaction falls within the purview of Related Party Transactions and the same is done at arm's Length. Valuation is based on the joint valuation report of M/s SSPA & Co and M/s Rajendra & Co, firms of Chartered Accountants duly approved by the Audit Committee. The transaction will be subject to the receipt of required approvals including that of the shareholders of the Company under Section 188 of Companies Act, 2013. The consent of the shareholders is proposed to be obtained through a postal ballot process.	
7.	Area of business of the entity (ies)	<u>E.I.D Parry (India) Limited (E.I.D. Parry)</u> E.I.D. Parry is a listed company engaged in the business of Sugar, Nutraceuticals and Bio Pesticides. <u>Coromandel International Limited</u> Fertilisers, Specialty Nutrients, Crop Protection and Rural Retail business.	
8.	Rationale for Slump sale	<ul style="list-style-type: none"> ➤ The transaction is part of the strategic plan of the Company to consolidate and focus on its Core businesses in Food and Nutraceuticals space. Also, it would help the Company to keep its gearing at a lower level to handle the Sugar Cyclical movements. ➤ It would help the Company to strengthen its balance sheet and focus on its Core businesses effectively. ➤ The Bio Products business would derive the synergy benefits by making inroads into South America, Africa and Asia where Coromandel has significant presence. Further, the Company would get benefited through the faster scale up of Bio Business under Coromandel fold by virtue of its majority stake in Coromandel. 	
9.	Brief details of change in shareholding (if any) of listed entity	No change in the shareholding pattern of E.I.D.- Parry India Limited	



Aswaji

